Ngozi Erondu Selected Research

trans- N- (1- (2- fluorophenyl)- 1h- pyrazol- 3- yl)- 1'- oxo- spiro(cyclohexane- 1,3'(1'H)- furo(3,4- C)pyridine)- 4- carboxamide

8/2007	NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.
4/2007	Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss.
10/2006	Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ngozi Erondu Research Topics

Disease

7	Weight Loss (Weight Reduction) 01/2008 - 02/2006
6	Type 2 Diabetes Mellitus (MODY) 01/2018 - 09/2015
5	Body Weight (Weight, Body) 01/2017 - 04/2007
3	Psoriasis (Pustulosis Palmaris et Plantaris) 02/2016 - 06/2015
2	Albuminuria 01/2018 - 01/2017
2	Overweight 01/2017 - 10/2006
2	Psoriatic Arthritis 02/2016 - 06/2014
2	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2016 - 09/2015
2	Pulmonary Tuberculosis 05/2013 - 06/2012
2	Obesity 12/2010 - 01/2008
1	Diabetes Mellitus 01/2018
1	Heart Failure 01/2018
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2018
1	Myocardial Infarction 01/2018
1	Stroke (Strokes) 01/2018
1	Renal Insufficiency (Renal Failure) 01/2017
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2017
1	Inflammation (Inflammations) 12/2016
1	Neutropenia 10/2015
1	Candidiasis (Moniliasis) 10/2015
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 09/2015
1	Ketosis 09/2015
1	Acidosis 09/2015
1	Rheumatoid Arthritis 06/2015
1	Tuberculosis (Tuberculoses) 02/2015
1	Rubella (German Measles) 11/2012
1	Mumps 11/2012
1	Measles 11/2012
1	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 06/2012
1	Body Weight Changes 05/2007

Drug/Important Bio-Agent (IBA)

7	CanagliflozinIBA 01/2018 - 09/2015
5	brodalumabIBA 02/2016 - 06/2014
3	Pharmaceutical PreparationsIBA 01/2018 - 05/2007
3	Monoclonal AntibodiesIBA 10/2015 - 06/2014
3	Interleukin-17 ReceptorsIBA 06/2015 - 06/2014
3	trans- N- (1- (2- fluorophenyl)- 1h- pyrazol- 3- yl)- 1'- oxo- spiro(cyclohexane- 1,3'(1'H)- furo(3,4- C)pyridine)- 4- carboxamideIBA 08/2007 - 10/2006
2	Sodium-Glucose Transport ProteinsIBA 01/2018 - 01/2017
2	Blood Glucose (Blood Sugar)IBA 01/2017 - 09/2015
2	N- (3- (4- chlorophenyl)- 2- (3- cyanophenyl)- 1- methylpropyl)- 2- methyl- 2- ((5- (trifluoromethyl)pyridin- 2- yl)oxy)propanamideIBA 12/2010 - 01/2008
2	neuropeptide Y5 receptorIBA 08/2007 - 10/2006
2	Neuropeptide YIBA 08/2007 - 04/2007
1	AlbuminsIBA 01/2018
1	CreatinineIBA 01/2018
1	SodiumIBA 01/2017
1	Glucose (Dextrose)FDA LinkGeneric 01/2017
1	SymportersIBA 01/2017
1	Phentermine (Adipex-P)FDA LinkGeneric 01/2017
1	Interleukin-17 (Interleukin 17)IBA 12/2016
1	CytokinesIBA 12/2016
1	Ustekinumab (CNTO 1275)FDA Link 10/2015
1	Insulin (Novolin)FDA Link 09/2015
1	Methotrexate (Mexate)FDA LinkGeneric 06/2015
1	RifamycinsIBA 02/2015
1	Rifampin (Rifampicin)FDA LinkGeneric 02/2015
1	rifapentine (Priftin)FDA Link 02/2015
1	bedaquiline (R207910)IBA 05/2013
1	Measles-Mumps-Rubella Vaccine (MMR Vaccine)IBA 11/2012
1	VaccinesIBA 11/2012
1	pretomanidIBA 06/2012
1	CannabinoidsIBA 01/2008
1	Hormones (Hormone)IBA 08/2007
1	sibutramine (Meridia)FDA Link 08/2007
1	Orlistat (Xenical)FDA Link 08/2007
1	peptide YY (3-36)IBA 05/2007
1	LeptinIBA 02/2006

Therapy/Procedure

2	Renal Replacement Therapy (Therapies, Renal Replacement) 01/2018 - 01/2017
2	Therapeutics 06/2015 - 01/2008
2	Caloric Restriction 04/2007 - 02/2007
1	Secondary Prevention 01/2018
1	Surgical Amputation (Amputations) 01/2017